Hu7691 free base (12.5-50 mg/kg/day; i.g.; for 22 days) shows dose-dependent tumor growth inhibition[1].
Hu7691 free base (15 mg/kg; oral) has a T1/2 of 8.68 hours, a Cmax of 171.17 ng/mL and an AUC of 2820.64 ng/mL h in rats[1].
Hu7691 free base (2 mg/kg; iv) has a T1/2 of 6.24 hours, a Cmax of 207.52 ng/mL and an AUC of 532.87 ng/mL h in rats[1].
Hu7691 free base (20 mg/kg; oral) has a T1/2 of 16.7 hours, a Cmax of 905.65 ng/mL and an AUC of 36303 ng/mL h in beagle dog (male, 40 weeks old, 8-10 kg)[1].
| Animal Model: | Balb/c mice (nu/nu, female, 3-4 weeks old, 20-25 g) with 786-O and KHOS xenograft[1] |
| Dosage: | 12.5, 25, 50 mg/kg |
| Administration: | Oral; once daily for 22 days |
| Result: | Showed dose-dependent tumor growth inhibition.
|
| Animal Model: | SD rats (male, 8 weeks old, 250-300 g)[1] |
| Dosage: | 15 mg/kg (Pharmacokinetic Analysis) |
| Administration: | Oral |
| Result: | Had a T1/2 of 8.68 hours, a Cmax of 171.17 ng/mL and an AUC of 2820.64 ng/mLh.
|